Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9359701 | 0.80 | CNR1 (0.35) | TSHRKDM4EHPGDHSD17B10ALDH1A1 | |
| SCHEMBL677325 | 0.78 | SLC6A2 (0.35) | DHODHGABRA1GABRB2 | |
| SCHEMBL6271210 | 0.78 | TDP1 (0.34) | KDM4EHPGDHSD17B10ALDH1A1 | |
| SCHEMBL19405532 | 0.77 | GRM2 (0.36) | DHODH | |
| SCHEMBL19405416 | 0.77 | SLC6A2 (0.38) | DHODHKDM4E | |
| SCHEMBL19405632 | 0.77 | DHODH (0.31) | DHODH | |
| SCHEMBL3589000 | 0.77 | CYP3A4 (0.33) | DHODH | |
| SCHEMBL6222946 | 0.77 | TYR (0.39) | TSHRHPGDTYRALDH1A1 | |
| SCHEMBL6868166 | 0.76 | BID (0.41) | TSHRKDM4EHSD17B10TYRALDH1A1 | |
| SCHEMBL1633732 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741242-B2 | Prepared by crosslinking a homogenized an addition polymer containing units from an unsaturated aryl-containing glycidyl ether or ester and an unsaturated alcohol or carboxylic acid and a zero-valent Pd compound to physically deposit the Pd compound on the polymer; oxidizing alcohols to aldehydes | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| EP-1537913-B1 | PALLADIUM CATALYST COMPOSITION | WAKO PURE CHEMICAL INDUSTIES L (JP) | 2009-07-01 | — | — | EP | disclosed |
| US-20060019822-A1 | Palladium catalyst composition | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1537913-A1 | PALLADIUM CATALYST COMPOSITION | Wako Pure Chemical Industies, Ltd. (JP) | 2005-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019822-A1 | Palladium catalyst composition | ODC1, NUDC, ADH1C | DHODH 1084/4885TSHR 4750/4885GABRA1 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.